AP662A - Anhydrous crystalline valaciclovir hydrochloride. - Google Patents

Anhydrous crystalline valaciclovir hydrochloride. Download PDF

Info

Publication number
AP662A
AP662A APAP/P/1997/001058A AP9701058A AP662A AP 662 A AP662 A AP 662A AP 9701058 A AP9701058 A AP 9701058A AP 662 A AP662 A AP 662A
Authority
AP
ARIPO
Prior art keywords
valaciclovir
hydrochloride
valaciclovir hydrochloride
crystalline
anhydrous crystalline
Prior art date
Application number
APAP/P/1997/001058A
Other languages
English (en)
Other versions
AP9701058A0 (en
Inventor
Carter Barry Howard
Partin Jane Muse
Varlashkin Peter Gregory
Winnike Richard Augustus
Grubb William Bayne
Conway Gregory Alan
Lake Philip George
Skinner David Michael
Whatrup David James
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9701058A0 publication Critical patent/AP9701058A0/xx
Application granted granted Critical
Publication of AP662A publication Critical patent/AP662A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001058A 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride. AP662A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
AP9701058A0 AP9701058A0 (en) 1997-10-31
AP662A true AP662A (en) 1998-08-19

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001058A AP662A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride.

Country Status (40)

Country Link
US (1) US6107302A (enEXAMPLES)
EP (1) EP0804436B1 (enEXAMPLES)
JP (1) JP3176633B2 (enEXAMPLES)
KR (1) KR100376074B1 (enEXAMPLES)
CN (1) CN1049893C (enEXAMPLES)
AP (1) AP662A (enEXAMPLES)
AR (1) AR002270A1 (enEXAMPLES)
AT (1) ATE302777T1 (enEXAMPLES)
AU (1) AU702794B2 (enEXAMPLES)
BG (1) BG63393B1 (enEXAMPLES)
BR (1) BR9606768A (enEXAMPLES)
CA (1) CA2210799C (enEXAMPLES)
CY (1) CY2531B1 (enEXAMPLES)
CZ (1) CZ297065B6 (enEXAMPLES)
DE (1) DE69635106T2 (enEXAMPLES)
DK (1) DK0804436T3 (enEXAMPLES)
EA (1) EA000364B1 (enEXAMPLES)
EE (1) EE03528B1 (enEXAMPLES)
ES (1) ES2248806T3 (enEXAMPLES)
FI (1) FI973063A7 (enEXAMPLES)
GB (1) GB9501178D0 (enEXAMPLES)
GE (1) GEP20001940B (enEXAMPLES)
HR (1) HRP960024B1 (enEXAMPLES)
HU (1) HU222993B1 (enEXAMPLES)
IL (1) IL116831A (enEXAMPLES)
IN (1) IN182468B (enEXAMPLES)
IS (1) IS2268B (enEXAMPLES)
NO (1) NO315558B1 (enEXAMPLES)
NZ (1) NZ298851A (enEXAMPLES)
OA (1) OA10499A (enEXAMPLES)
PL (1) PL182175B1 (enEXAMPLES)
RO (1) RO118693B1 (enEXAMPLES)
RS (1) RS49518B (enEXAMPLES)
SI (1) SI0804436T1 (enEXAMPLES)
SK (1) SK285329B6 (enEXAMPLES)
TR (1) TR199700656T1 (enEXAMPLES)
UA (1) UA46001C2 (enEXAMPLES)
UY (1) UY25779A1 (enEXAMPLES)
WO (1) WO1996022291A1 (enEXAMPLES)
ZA (1) ZA96449B (enEXAMPLES)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DE69726255T2 (de) * 1996-01-19 2004-08-26 Glaxo Group Ltd., Greenford Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
SK1592004A3 (sk) * 2001-09-07 2005-03-04 Teva Pharmaceutical Industries Ltd. Kryštalické formy valaciklovírus hydrochlóridu
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
HRP20040511A2 (en) * 2001-11-14 2004-10-31 Teva Pharma Synthesis and purification of valacyclovir
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE60307494D1 (de) * 2002-10-16 2006-09-21 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
US20050192296A1 (en) * 2004-01-21 2005-09-01 Zvi Harel Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
JP5843855B2 (ja) 2010-06-24 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病療法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
EP0596542B1 (en) * 1987-08-15 1996-05-29 The Wellcome Foundation Limited Therapeutic nucleosides
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Also Published As

Publication number Publication date
EA199700124A1 (ru) 1997-12-30
CA2210799C (en) 2008-06-10
US6107302A (en) 2000-08-22
ES2248806T3 (es) 2006-03-16
UA46001C2 (uk) 2002-05-15
FI973063A0 (fi) 1997-07-18
PL321326A1 (en) 1997-12-08
NO973326L (no) 1997-09-16
IS4527A (is) 1997-07-15
AU4453996A (en) 1996-08-07
RO118693B1 (ro) 2003-09-30
JPH11503718A (ja) 1999-03-30
EA000364B1 (ru) 1999-06-24
SK285329B6 (sk) 2006-11-03
IS2268B (is) 2007-07-15
YU3396A (sh) 1998-12-23
OA10499A (en) 2002-04-10
NO315558B1 (no) 2003-09-22
FI973063L (fi) 1997-09-18
CY2531B1 (en) 2006-04-12
DK0804436T3 (da) 2005-12-27
HU222993B1 (hu) 2004-01-28
IL116831A (en) 1998-10-30
GEP20001940B (en) 2000-02-05
CA2210799A1 (en) 1996-07-25
CN1179159A (zh) 1998-04-15
ZA96449B (en) 1996-08-07
HUP9801836A2 (hu) 1999-05-28
HRP960024B1 (en) 2005-08-31
KR100376074B1 (ko) 2003-06-02
UY25779A1 (es) 2000-08-21
AP9701058A0 (en) 1997-10-31
DE69635106T2 (de) 2006-06-08
EP0804436A1 (en) 1997-11-05
WO1996022291A1 (en) 1996-07-25
CZ229497A3 (en) 1997-12-17
SK96597A3 (en) 1998-02-04
TR199700656T1 (xx) 1998-03-21
IN182468B (enEXAMPLES) 1999-04-17
BG101833A (bg) 1998-04-30
EP0804436B1 (en) 2005-08-24
IL116831A0 (en) 1996-05-14
HRP960024A2 (en) 1997-10-31
EE9700175A (et) 1998-02-16
AU702794B2 (en) 1999-03-04
HUP9801836A3 (en) 1999-06-28
MX9705462A (es) 1997-10-31
EE03528B1 (et) 2001-10-15
SI0804436T1 (sl) 2006-02-28
KR19980701525A (ko) 1998-05-15
DE69635106D1 (de) 2005-09-29
NZ298851A (en) 1999-01-28
ATE302777T1 (de) 2005-09-15
GB9501178D0 (en) 1995-03-08
NO973326D0 (no) 1997-07-18
RS49518B (sr) 2006-10-27
FI973063A7 (fi) 1997-09-18
PL182175B1 (pl) 2001-11-30
BR9606768A (pt) 1997-12-30
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
JP3176633B2 (ja) 2001-06-18
AR002270A1 (es) 1998-03-11
CZ297065B6 (cs) 2006-08-16

Similar Documents

Publication Publication Date Title
AP662A (en) Anhydrous crystalline valaciclovir hydrochloride.
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
CA2243237C (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
HK1003055B (en) Guanine derivative
HK1003055A1 (en) Guanine derivative
MXPA97005462A (en) Derived from guan
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color